Malignant liver tumours include a wide range of primary and secondary tumours. Although
surgery remains the mainstay of curative treatment, modern therapies integrate a variety of …

The liver is the commonest site of metastatic disease for patients with colorectal cancer, with
at least 25% developing colorectal liver metastases (CRLM) during the course of their …

Colorectal cancer is a prevalent disease worldwide, with more than 50% of patients
developing metastases to the liver. Despite advances in improving resectability, most …

An international panel of multidisciplinary experts convened to develop recommendations
for managing patients with colorectal cancer (CRC) and synchronous liver metastases …

An international panel of multidisciplinary experts convened to develop recommendations
for the management of patients with liver metastases from colorectal cancer (CRC). The aim …

Objective: To examine recurrence and survival rates for patients treated with hepatic
resection only, radiofrequency ablation (RFA) plus resection or RFA only for colorectal liver …

Liver cirrhosis, the end-stage of every chronic liver disease, is not only the major risk factor
for the development of hepatocellular carcinoma but also a limiting factor for anticancer …

Objective: To evaluate the long-term survival of patients resected for primarily unresectable
colorectal liver metastases (CRLM) downstaged by systemic chemotherapy and to use …

The safe removal of extensive tumor load in the liver has been one of the main focuses of
laboratory and clinical research for hepato-biliary surgeons over the past 3 decades. 1 The …

Colorectal cancer liver metastases (CRLM) represent most of the causes of death in patients
with colorectal cancer. Surgical resection is the only treatment that can provide the …